Eli Lilly and Company Share Price Euronext Paris

Equities

LLY

US5324571083

Pharmaceuticals

Real-time Euronext Paris 15:05:35 29/10/2019 GMT 5-day change 1st Jan Change
98 EUR -1.01% Intraday chart for Eli Lilly and Company -.--% +2.08%

Financials

Sales 2024 * 42.98B 40.13B 3,397B Sales 2025 * 52.62B 49.13B 4,159B Capitalization 811B 758B 64,133B
Net income 2024 * 11.93B 11.14B 943B Net income 2025 * 16.55B 15.45B 1,308B EV / Sales 2024 * 19.3 x
Net Debt 2024 * 18.06B 16.86B 1,427B Net Debt 2025 * 15B 14B 1,185B EV / Sales 2025 * 15.7 x
P/E ratio 2024 *
67.4 x
P/E ratio 2025 *
48.5 x
Employees -
Yield 2024 *
0.58%
Yield 2025 *
0.66%
Free-Float 99.8%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 56 31/12/95
President - -
Chief Tech/Sci/R&D Officer - 15/10/23
Members of the board TitleAgeSince
Director/Board Member 63 24/01/21
Director/Board Member 68 31/03/09
Director/Board Member 63 31/12/04
More insiders
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows: - endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems; - oncology (19.5%); - immunology diseases (11.1%); - neurology (8.4%): primarily drugs used in treating depression and schizophrenia; - other (3.3%). Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
901.3 USD
Average target price
860.5 USD
Spread / Average Target
-4.52%
Consensus